Abstract: Objective To analyze the pharmaceutical care given by a clinical pharmacist for an elderly patient with pulmonary mucormycosis who developed severe hypokalemia in order to provide references for safe clinical use. Methods A clinical pharmacist was involved in the pharmaceutical care for a patient who had underlying hypokalemia and experienced more decline in serum potassium levels during ABCD treatment for pulmonary mucormycosis. During the pharmaceutical care, the pharmacist assessed the rationality of the ABCD dosage and administration route, investigated the causes of recurrent hypokalemia, calculated the required potassium supplementation dose, and adjusted the potassium correction regimen. Results With the help of the clinical pharmacist, the patient received systemic and local ABCD treatment for pulmonary mucormycosis, along with oral and intravenous potassium supplementation to address hypokalemia. Following active antifungal therapy, the patient's condition stabilized, with negative results on follow-up fungal tests, and serum potassium levels were promptly corrected. Conclusion The clinical pharmacist has played a proactive role in the geriatric treatment team by analyzing the rationality of individualized, multi-route ABCD administration for pulmonary mucormycosis in elderly patients. The pharmacist has showed a keen ability to identify adverse reactions associated with ABCD-induced hypokalemia and assisted physicians in formulating scientific potassium supplementation regimens, effectively reducing adverse drug reactions while achieving favorable therapeutic outcomes.

Key words: Amphotericin B Cholesteryl Sulfate Complex, Elderly Patients, Pulmonary Mucormycosis, Hypokalemia, Pharmaceutical Care